ReviewAnnals of translational medicine2015
MicroRNA and MET in lung cancer.
Review in Annals of translational medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 31 citations in OpenAlex.
- PDLIM2 acts as a central regulator of ubiquitination, immune signaling, and mitochondrial metabolism in lung cancer suppression (Review).International journal of oncology · 2026Review
- "Crosstalk between non-coding RNAs and transcription factor LRF in non-small cell lung cancer".Non-coding RNA research · 2024Article
- A-to-I edited miR-411-5p targets MET and promotes TKI response in NSCLC-resistant cells.Oncogene · 2023Article
- Article
- Exosome-Mediated miR-21 Was Involved in the Promotion of Structural and Functional Recovery Effect Produced by Electroacupuncture in Sciatic Nerve Injury.Oxidative medicine and cellular longevity · 2022Article
- Curcumin in Combination with Other Adjunct Therapies for Brain Tumor Treatment: Existing Knowledge and Blueprint for Future Research.International journal of molecular and cellular medicine · 2021Review
- The Association of microRNA-34a With High Incidence and Metastasis of Lung Cancer in Gejiu and Xuanwei Yunnan.Frontiers in oncology · 2021Article
- [Serum MiRNA as Predictive and Prognosis Biomarker in Advanced Stage Non-small Cell Lung Cancer in Indonesia].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2020Article
- Intercalating the Role of MicroRNAs in Cancer: As Enemy or Protector.Asian Pacific journal of cancer prevention : APJCP · 2020Review
- Radiosensitizing effects of miR-18a-5p on lung cancer stem-like cells via downregulating both ATM and HIF-1α.Cancer medicine · 2018Article
- miRNAs as Biomarkers and Therapeutic Targets in Non-Small Cell Lung Cancer: Current Perspectives.Targeted oncology · 2017Review
- Genetic and epigenetic silencing of mircoRNA-506-3p enhances COTL1 oncogene expression to foster non-small lung cancer progression.Oncotarget · 2017Article
- Exploring conserved mRNA-miRNA interactions in colon and lung cancers.Gastroenterology and hepatology from bed to bench · 2017Article
- Modification of tumor cell exosome content by transfection with wt-p53 and microRNA-125b expressing plasmid DNA and its effect on macrophage polarization.Oncogenesis · 2016Article
- Overexpression of MicroRNA-221 is associated with poor prognosis in non-small cell lung cancer patients.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2016Article
- Integrative microRNA and gene profiling data analysis reveals novel biomarkers and mechanisms for lung cancer.Oncotarget · 2016Article
- Oncogenic miR-137 contributes to cisplatin resistance via repressing CASP3 in lung adenocarcinoma.American journal of cancer research · 2016Article
- EPHX1 rs2234922 polymorphism and lung cancer susceptibility in Asian populations: a meta-analysis.Journal of thoracic disease · 2015Article
- The Impact of Neuroimmune Alterations in Autism Spectrum Disorder.Frontiers in psychiatry · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
MicroRNAs (miRNAs) are a class of small non-protein coding RNAs that modulate important cellular functions via their post-transcriptional regulation of messenger RNAs (mRNAs). Recent evidences from multiple tumor types and model systems implicate miRNA dysregulation as a common mechanism of tumorigenesis, cancer progression and resistance to therapy. Several miRNAs are dysregulated in cancers and a single miRNA can have multiple targets involved in different oncogenic pathways. MET, the tyrosine kinase receptor for hepatocyte growth factor (HGF), has a central role in lung cancer development and in acquired resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors; it has been predicted and shown to be the target gene of multiple miRNAs, which play a crucial role in controlling its activity in a stimulatory or inhibitory sense. In this review we will focus on the most important and recent studies about the role of miRNAs in the control of MET expression, reporting also the progress made using miRNAs for therapy of lung cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.